Kura Oncology, Inc.

KURA · Nasdaq · United States

Share price · KURA

$7.34-4.99 (-40.47%) 3M

close as of 2026-11-18 · 24h delayed · vol 2.5M (1.1x 30-day avg)

Loading chart…

Prices are end-of-day (EOD), delayed by 24 hours · Adjusted for stock splits · Data via Databento

Compare with peers →

Unusual price moves

Days when KURA's shares moved far more than they usually do, with what was announced that day or the session before. An announcement on the same day does not show that it caused the move. How the days are picked

  1. 4 Nov 2026-23.0%
  2. 28 Oct 2026+8.3%
  3. 25 Aug 2026+9.6%
  4. 18 Aug 2026+9.3%
  5. 14 Aug 2026+7.6%
  6. 28 Jul 2026-8.3%
  7. 7 Jul 2026+8.6%
  8. 1 Jun 2026-11.4%
  9. 26 May 2026-7.5%
  10. 21 May 2026+7.6%

Share of unusual movement by asset

For each asset, the share of KURA's own-move activity since 2 Jul 2024 that fell on the session of one of the asset's own announcements or the session after it. Large moves count for much more than small ones. A session shared by several assets is split between them. A share is shown once an asset has at least 8 event days; below that, its events are listed instead.

AssetEvent daysShare of unusual movement
Ziftomenib
events and moves
5shown from 8 days
Darlifarnib
events and moves
3shown from 8 days
Assets with fewer than 8 event days, together—12%
Other company news (earnings, financing, releases naming no asset)—30%
Sessions with no dated event—57%

Assets

(2 total)
2Total Assets
1Approved
0Phase 3 / Filed
1Phase 1–2 / Early
4Diseases
Quick filter:
Showing 2 of 2 assets
Target & Modality
Approved
MeninSmall molecule
Acute Myeloid LeukemiaAcute Lymphoblastic Leukemia
Relapsed/Refractory Acute Myeloid Leukemia
Phase 1
FarnesyltransferaseSmall molecule
Non-Small Cell Lung CancerRenal Cell Carcinoma
Clear Cell Renal Cell Carcinoma

Upcoming events

(3 total)

Estimated primary-completion dates from ClinicalTrials.gov and expected earnings reports. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Add these trial readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2027 (1)
March 2027 (1)
ZiftomenibPhase 2Acute Myeloid Leukemia (AML)
Est. primary completion 2027-03 · NCT07623616 · CT.gov ↗
What to watch
2028 (1)
October 2028 (1)
ZiftomenibPhase 1/2Advanced Malignant Neoplasm, Acute Myeloid Leukemia, Mixed Lineage Leukemia, Mixed Lineage Acute Leukemia …
Est. primary completion 2028-10-16 · NCT04067336 · CT.gov ↗
What to watch
2031 (1)
November 2031 (1)
ZiftomenibPhase 3Acute Myeloid Leukemia (AML)
Est. primary completion 2031-11 · NCT07007312 · CT.gov ↗
What to watch

See the full readout calendar ↗

Regulatory and conference events

(1)

Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.

Recent

13 November 2025ApprovalZiftomenibFDA Boxed Warning on Ziftomenib (NDA220305)
US, FDA · FDA · Source ↗

Financial reports

Quarterly & interim (17)

PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2026-Q3$23M$67M$58M+ $434M short-term inv.$70M-$54M operating cash flowreport ↗
View 16 more
PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2026-Q2$21M$62M$70M+ $449M short-term inv.$68M-$63M operating cash flowreport ↗
2026-Q1$18M$65M$39M+ $542M short-term inv.$73M-$86M operating cash flowreport ↗
2025-Q4$17M$64M$667M$81Mreport ↗
2025-Q3$21M$68M$95M+ $454M short-term inv.$74M-$81M operating cash flowreport ↗
2025-Q2$15M$63M$82M+ $549M short-term inv.$66M-$29M operating cash flowreport ↗
2025-Q1$18M$56M$658M$73Mreport ↗
2024-Q3—$42M$49M+ $406M short-term inv.$54M-$43M operating cash flowreport ↗
2024-Q2—$40M$45M+ $446M short-term inv.$51M-$43M operating cash flowreport ↗
2024-Q1—$36M$42M+ $486M short-term inv.$50M-$49M operating cash flowreport ↗
2023-Q3—$29M$29M+ $424M short-term inv.$39M-$29M operating cash flowreport ↗
2023-Q2—$28M$49M+ $428M short-term inv.$37M-$26M operating cash flowreport ↗
2023-Q1—$25M$27M+ $379M short-term inv.$34M-$36M operating cash flowreport ↗
2022-Q3—$25M$91M+ $337M short-term inv.$36M-$21M operating cash flowreport ↗
2022-Q2—$24M$39M+ $411M short-term inv.$35M-$30M operating cash flowreport ↗
2022-Q1—$21M$34M+ $446M short-term inv.$32M-$32M operating cash flowreport ↗
2021-Q3—$22M$39M+ $504M short-term inv.$33M-$25M operating cash flowreport ↗

Annual history (5 years)

PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2025-FY$68M$251M$667M$295Mreport ↗
View 4 more years
PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2024-FY——$727M—report ↗
2023-FY$0$115M$37M+ $387M short-term inv.$38M-$125M operating cash flowreport ↗
2022-FY—$93M$52M+ $386M short-term inv.$34M-$110M operating cash flowreport ↗
2021-FY—$85M$91M+ $427M short-term inv.$33M-$105M operating cash flowreport ↗

Insider transactions

Open-market activity, trailing 12 months: 6 purchases ($5.4M), 44 sales ($4.0M). Awards, option exercises and tax-withholding rows are listed below but excluded from these totals.

Source
2026-11-19Powl Brian T. · Chief Commercial OfficerOpen-market sale448$7.27$3KForm 4
2026-11-17FORD KATHLEEN · Chief Operating OfficerOpen-market sale3,668$7.46$27KForm 4
2026-11-17Powl Brian T. · Chief Commercial OfficerOpen-market sale15,254$7.45$114KForm 4
2026-11-17Leoni Mollie · Chief Medical OfficerOpen-market sale22,241$7.45$166KForm 4
2026-11-16FORD KATHLEEN · Chief Operating OfficerOpen-market sale7,042$7.44$52KForm 4
2026-11-16Bair Teresa Brophy · Chief Legal OfficerOpen-market sale8,601$7.44$64KForm 4
2026-11-16Powl Brian T. · Chief Commercial OfficerOpen-market sale9,196$7.44$68KForm 4
2026-11-16Leoni Mollie · Chief Medical OfficerOpen-market sale19,009$7.44$141KForm 4

Institutional holders

From SEC Form 13F filings for the quarter ended 2026-03-31 (filed up to 45 days later). 218 reporting institutions held 84.4M shares ($675.4M, 91.8% of shares outstanding).

#InstitutionSharesValue
1BlackRock, Inc.9,637,531$78.4M
2SUVRETTA CAPITAL MANAGEMENT, LLC8,575,422$69.7M
3BVF INC/IL8,445,769$68.7M
4STATE STREET CORP4,511,891$36.7M
5VANGUARD CAPITAL MANAGEMENT LLC3,785,685$30.8M
6ARMISTICE CAPITAL, LLC3,736,000$30.4M
7Prosight Management, LP3,356,700$27.3M
8Deep Track Capital, LP2,643,542$21.5M
9AQR CAPITAL MANAGEMENT LLC2,124,480$17.3M
10GEODE CAPITAL MANAGEMENT, LLC2,034,276$16.5M
11Qube Research & Technologies Ltd1,636,733$13.3M
12RENAISSANCE TECHNOLOGIES LLC1,582,568$12.9M
13MILLENNIUM MANAGEMENT LLC1,565,143$12.7M
14ALETHEA CAPITAL MANAGEMENT, LLC1,529,369$12.4M
15GOLDMAN SACHS GROUP INC1,433,471$11.7M